Intratio
Quantitative Research
Skip to main content
AI Market Summary
Loading market intelligence...
AI 90-DAY FORECAST
NEUTRAL SIGNAL
██.█% Sign up free to reveal

Glaukos Corp (GKOS) AI Forecast

Our AI analyzed Glaukos Corp. Create a free account to see the 90-day price prediction.

Free account • 30-day free trial

$GKOS Neutral Signal Full forecast available

Glaukos Corp (GKOS) AI Stock Price Forecast & Investment Analysis

Glaukos Corp Stock Price Chart and Technical Analysis

Loading chart...

Glaukos Corp (GKOS) - Comprehensive Stock Analysis & Investment Research

Deep dive into Glaukos Corp's business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Analysis updated on March 12, 2026, 7:28 p.m. (UTC)

Glaukos Corp Investment Summary

When evaluating whether Glaukos Corp (GKOS) represents a compelling investment opportunity, investors must consider multiple factors including the company's financial health, market position, growth prospects, and what our AI-powered predictive models suggest about its near-term price trajectory.

Company Profile

Glaukos Corp (GKOS) operates within the Industrial Applications and Services sector, specifically in the Surgical & Medical Instruments & Apparatus industry. The company employs approximately 654 people. With a market capitalization of $6 billion, the company is a mid-cap stock that typically offers a balance between growth potential and established business operations.

Financial Performance Analysis

Our comprehensive financial analysis covers Glaukos Corp's revenue, profitability metrics, balance sheet strength, and cash flow generation...

AI Price Predictions

Get AI-powered 7-day, 30-day and 90-day price forecasts for Glaukos Corp along with confidence scores and detailed analysis...

Investment Considerations

Expert analysis of whether Glaukos Corp is suitable for your investment objectives, risk tolerance, and time horizon...

Continue Reading Full Analysis

Get the complete investment breakdown for Glaukos Corp

Sign Up Free
Corporate Identity

Glaukos Corp (Stock Symbol: GKOS) is a prominent company operating within the Industrial Applications and Services sector, with a specific focus on the Surgical & Medical Instruments & Apparatus industry. The company's shares are publicly traded on the NYSE exchange.

Leadership & Workforce

Detailed information about Glaukos Corp's leadership team, workforce size, and organizational structure...

Market Classification

Market capitalization analysis and stock classification (mega-cap, large-cap, mid-cap, small-cap) for Glaukos Corp...

Sector & Industry Analysis

In-depth sector dynamics and industry context for Glaukos Corp...

Unlock Full Company Profile

Get complete details about Glaukos Corp

Sign Up Free
Revenue & Growth Analysis

Glaukos Corp generates annual revenues of $507 million , representing an emerging company in its growth phase.

Profitability Metrics

Net profit margin, gross margin, and operating margin analysis for Glaukos Corp...

Market Valuation

P/E ratio, price-to-book, and valuation multiples for Glaukos Corp...

Return Metrics

Return on equity (ROE), return on assets (ROA), and capital efficiency for Glaukos Corp...

Unlock Financial Analysis

Get complete financial metrics for Glaukos Corp

Sign Up Free
AI ANALYSIS AVAILABLE

Unlock Glaukos Corp's AI Price Forecast

Join 10,000+ investors using our 67%+ accurate AI predictions

4,000+ Stocks Analyzed
67%+ Accuracy Rate
Daily Updates
Start 30-Day Free Trial

30-day free trial • Cancel anytime

Strategic Market Position

Glaukos Corp strategically competes in the highly dynamic Surgical & Medical Instruments & Apparatus marketplace. As a mid-cap company, it occupies an attractive position balancing growth potential with established operations. Mid-caps often represent the 'sweet spot' for investors seeking companies that have proven their business models but still have meaningful runway for expansion. These companies are large enough to have competitive advantages but nimble enough to adapt quickly to market changes.

Industry Competitive Landscape

Glaukos Corp competes within the Industrial Applications and Services sector, navigating the competitive dynamics and market forces specific to this industry. The company's competitive position depends on its ability to differentiate through product quality, cost efficiency, customer relationships, or other strategic advantages relevant to its specific market segment.

Operational Efficiency

The company currently shows negative free cash flow of $-7 million , with year-over-year cash flow growth of -26.1%. Negative free cash flow may reflect heavy investment in growth, working capital needs, or operational challenges. This is common for high-growth companies investing aggressively but warrants attention for mature businesses.

Margin & Pricing Power Analysis

The company maintains a 77.2% gross margin which reflects exceptional pricing power and/or an asset-light business model. Gross margins at this level are typically seen in software, pharmaceuticals, or luxury goods companies where the cost of incremental production is minimal relative to selling prices. Such margins indicate significant competitive advantages protecting the company from price-based competition.

Operating margin of -20.9% demonstrates how efficiently the company converts revenues into operating profits after accounting for all operating expenses including research and development, sales and marketing, and general administrative costs. Operating margin compression relative to gross margin suggests high operating expenses that may warrant efficiency improvements or reflect necessary growth investments.

Asset Utilization Efficiency

Asset turnover ratio of 0.28x indicates lower asset turnover that may reflect the industry's capital-intensive nature or potentially underutilized assets. Companies with low turnover typically depend on strong margins to generate adequate returns on capital.

Financial Strength & Leverage

Current ratio of 8.84 demonstrates strong short-term liquidity with current assets significantly exceeding current liabilities. This provides a substantial buffer for meeting near-term obligations and handling unexpected financial needs.

Glaukos Corp (GKOS) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Glaukos Corp stock analysis.

Deep dive into Glaukos Corp's financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Glaukos Corp stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Glaukos Corp: With a P/E ratio of -46.26, the market sees the stock as potentially undervalued.

P/E Ratio -46.26x
P/B Ratio 9.02x
Market Cap $5.92B
EPS $-1.61
Book Value/Share $11.41
Revenue/Share $8.82
FCF/Share $-0.93
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Glaukos Corp converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Glaukos Corp: An ROE of -4.7% indicates room for improvement in shareholder value creation.

ROE -4.7%
ROA -2.7%
ROIC -2.5%
Gross Margin 77.2%
Operating Margin -20.9%
Net Margin -9.5%
EBT Margin -9.3%
Tax Rate 0.9%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Glaukos Corp's ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Glaukos Corp: A current ratio of 8.84 indicates strong liquidity.

Current Ratio 8.84x
Quick Ratio 8.10x
D/E Ratio 0.64x
Financial Leverage 1.76x
Interest Coverage -1.0x
Working Capital $420M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Glaukos Corp's ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Glaukos Corp: Free cash flow of $-7M indicates cash challenges that need attention.

Operating Cash Flow $30M
Free Cash Flow -$7M
Capital Spending -$37M
OCF Growth YoY -26.1%
FCF Growth YoY -55.5%
FCF/Sales -2.4%
CapEx/Sales 12.7%
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Glaukos Corp uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Glaukos Corp: An asset turnover of 0.28x suggests room for improvement in asset utilization.

Asset Turnover 0.28x
Receivables Turnover 8.2x
Inventory Turnover 3.4x
Fixed Assets Turnover 2.2x
Days Sales Outstanding 44 days
Days Inventory 109 days
Payables Period 45 days
Cash Conversion Cycle 108 days
Understanding Financial Statement Data

What these metrics mean: Key figures from Glaukos Corp's income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Glaukos Corp: With annual revenue of $507M, Glaukos Corp demonstrates solid business size.

Income Statement
Total Revenue $507M
R&D Expense $14M
SG&A Expense $62M
Cost of Goods Sold $84M
Balance Sheet Highlights (% Of Assets)
Total Current Assets 47%
Cash & Short-term Investments 39%
Total Liabilities 43%
Short-term Debt 27%
Accounts Receivable 3%
Inventory 2%
Dividend & Shareholder Information
Shares Outstanding 58M
Growth Metrics (YoY)
EPS Growth -2.0%

Latest Glaukos Corp Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Glaukos Corp (GKOS) stock price and investment outlook.

source: Nasdaq

Investors in Glaukos Corp (Symbol: GKOS) saw new options begin trading today, for the September 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the GKOS ...

source: San Antonio Express-News

What: Shares of Glaukos Corp. , a medical device company primarily focused on creating products that treat glaucoma, soared more than higher 26% as of 11:15 a.m. EST Wednesday after the company ...

More news available

Sign up free to read all 9 news articles and stay updated on market developments.

Sign Up Free to Read More

Glaukos Corp Competitors & Peer Analysis - Industrial Applications and Services Sector

Comparative analysis of Glaukos Corp against industry peers and competitors in the Industrial Applications and Services sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio
Adagio Medical Holdings, Inc. ADGM ██% $21M x 2.4x
Aethlon Medical Inc AEMD ██% $2M -0.1x 0.3x
Acutus Medical, Inc. AFIB ██% $0.00M 0.0x -0.4x
Allurion Technologies, Inc. ALUR ██% $11M -0.4x -0.3x
Autonomix Medical, Inc. AMIX ██% $5M x 0.5x
Angiodynamics Inc ANGO ██% $459M -1.4x 2.6x
Anika Therapeutics, Inc. ANIK ██% $196M -4.3x 1.4x
Artivion, Inc. AORT ██% $1.68B 171.9x 3.8x
Apyx Medical Corp APYX ██% $118M -3.5x 20.2x
Accuray Inc ARAY ██% $54M -9.9x 1.0x
Alphatec Holdings, Inc. ATEC ██% $1.90B -7.4x 153.1x
Atricure, Inc. ATRC ██% $1.49B -39.6x 3.0x
Nuo Therapeutics, Inc. AURX ██% $60M x 67.8x
Avita Medical, Inc. AVHHL ██% $22M x x
Baxter International Inc BAX ██% $8.96B -94.9x 1.5x
Beta Bionics, Inc. BBNX ██% $482M x 1.7x
Becton Dickinson & Co BDX ██% $59.37B 33.8x 2.4x
Heartbeam, Inc. BEAT ██% $54M -5.7x 133.4x
Bluejay Diagnostics, Inc. BJDX ██% $2M -0.5x 0.3x
Boston Scientific Corp BSX ██% $103.08B 35.6x 4.3x
Biotricity Inc. BTCY ██% $6M -2.7x 2.8x
Bioventus Inc. BVS ██% $593M 26.1x 3.2x
Brainsway Ltd. BWAY ██% $499M x x
Carlsmed, Inc. CARL ██% $311M x 3.2x
Cerus Corp CERS ██% $344M -13.8x 5.4x
Clearpoint Neuro, Inc. CLPT ██% $330M -23.5x 20.8x
Co-Diagnostics, Inc. CODX ██% $7M -0.7x 0.2x
Cytosorbents Corp CTSO ██% $46M -1.8x 5.1x
Cvrx, Inc. CVRX ██% $206M -5.5x 5.2x
Delcath Systems, Inc. DCTH ██% $336M 124.4x 3.0x
Dih Holding Us, Inc. DHAI ██% $70K x -0.3x
Dariohealth Corp. DRIO ██% $60M 0.6x 0.8x
Alpha Tau Medical Ltd. DRTS ██% $620M x 8.0x
Dexcom Inc DXCM ██% $25.52B 30.5x 9.3x
Dynatronics Corp DYNT ██% $540K -0.2x 0.2x
Ebr Systems, Inc. EBRCZ ██% $234M x 6.1x
Encision Inc ECIA ██% $3M x 1.4x
Embecta Corp. EMBC ██% $533M 3.8x -0.8x
Electromedical Technologies, Inc EMED ██% $750K x x
Femasys Inc FEMY ██% $34M -1.4x 7.5x
Family Office Of America, Inc. FOFA ██% $89M x 110.9x
Glucotrack, Inc. GCTK ██% $1M 0.9x 0.5x
Global Innovative Platforms Inc. GIPL ██% $320K x 2.0x
Glaukos Corp GKOS ██% $5.92B -46.3x 9.0x
Globus Medical Inc GMED ██% $11.79B 21.9x 2.6x
Fractyl Health, Inc. GUTS ██% $72M x 11.3x
Haemonetics Corp HAE ██% $2.84B 16.2x 3.1x
Harvard Apparatus Regenerative Technology, Inc. HRGN ██% $29M x 18.9x
Integra Lifesciences Holdings Corp IART ██% $737M 200.2x 0.7x
Icecure Medical Ltd. ICCM ██% $46M x 16.0x
Seastar Medical Holding Corp ICU ██% $88M -1.1x 7.7x
Icu Medical Inc/De ICUI ██% $3.30B 4511.3x 1.6x
Interpace Biosciences, Inc. IDXG ██% $48M 9.9x 7.0x
Inspira Technologies Oxy B.H.N. Ltd IINN ██% $25M x 5.8x
Inspira Technologies Oxy B.H.N. Ltd IINNW ██% $7M x 1.5x
Intelligent Bio Solutions Inc. INBS ██% $7M -0.3x 0.6x
Infusystem Holdings, Inc INFU ██% $169M 30.5x 3.0x
Inspire Medical Systems, Inc. INSP ██% $1.70B 11.7x 2.2x
Iradimed Corp IRMD ██% $1.26B 56.3x 13.4x
Irhythm Holdings, Inc. IRTC ██% $3.86B -20.2x 25.3x
Invo Fertility, Inc. IVF ██% $6M x 1.0x
Orthopediatrics Corp KIDS ██% $447M -20.7x 1.3x
Kestra Medical Technologies, Ltd. KMTS ██% $1.30B x x
Koru Medical Systems, Inc. KRMD ██% $211M -19.8x 12.8x
Lemaitre Vascular Inc LMAT ██% $2.47B 42.7x 6.3x
Lensar, Inc. LNSR ██% $140M -6.7x 28.7x
Lucid Diagnostics Inc. LUCD ██% $199M -0.6x 7.7x
Pulmonx Corp LUNG ██% $74M -4.3x 1.4x
Lyra Therapeutics, Inc. LYRA ██% $2M -0.1x 1.3x
Microbot Medical Inc. MBOT ██% $191M -1.3x 2.5x
Mountain Crest Acquisition Corp. V MCAG ██% $34M x 1509.8x
Mountain Crest Acquisition Corp. V MCAGU ██% $31M x -9.9x
Spectral Ai, Inc. MDAI ██% $43M -1.3x 29.5x
Medinotec Inc. MDNC ██% $59M 25.1x 10.7x
Mimedx Group, Inc. MDXG ██% $677M 13.9x 2.6x
Monogram Technologies Inc. MGRM ██% $217M -10.7x 25.1x
Meihua International Medical Technologies Co., Ltd. MHUA ██% $151M x 0.9x
3m Co MMM ██% $82.28B 25.3x 17.5x
Merit Medical Systems Inc MMSI ██% $4.32B 33.6x 2.7x
Modular Medical, Inc. MODD ██% $31M -2.1x 5.2x
Nephros Inc NEPH ██% $42M 28.2x 5.0x
Neuroone Medical Technologies Corp NMTC ██% $40M -1.7x 6.2x
Neuropace Inc NPCE ██% $491M -10.4x 25.8x
Inspiremd, Inc. NSPR ██% $68M -4.3x 1.1x
Nu-Med Plus, Inc. NUMD ██% $1M x 5.3x
Novocure Ltd NVCR ██% $1.39B -20.8x 4.1x
Envveno Medical Corp NVNO ██% $8M x 0.3x
Nexgel, Inc. NXGL ██% $9M -6.8x 1.8x
Nyxoah Sa NYXH ██% $157M x x
Orchestra Biomed Holdings, Inc. OBIO ██% $262M -3.4x 2.6x
Odyssey Health, Inc. ODYY ██% $5M x 0.7x
Orthofix Medical Inc. OFIX ██% $487M -5.8x 1.1x
Osr Holdings, Inc. OSRH ██% $11M x 0.1x
Orasure Technologies Inc OSUR ██% $214M 17.1x 0.6x
Pavmed Inc. PAVM ██% $10M 3.1x 0.3x
Pro Dex Inc PDEX ██% $145M 12.8x 3.5x
Penumbra Inc PEN ██% $13.28B 74.8x 9.3x
Petvivo Holdings, Inc. PETV ██% $28M -1.4x 8.4x
Polyrizon Ltd. PLRZ ██% $13M x 0.7x
Pulse Biosciences, Inc. PLSE ██% $1.39B -2.6x 17.2x
Picard Medical, Inc. PMI ██% $85M x 10.7x
Insulet Corp PODD ██% $16.68B 67.5x 11.0x
Procept Biorobotics Corp PRCT ██% $1.51B -45.4x 4.1x
Premier Air Charter Holdings Inc. PREM ██% $2M x 2.4x
Profound Medical Corp. PROF ██% $213M x 3.2x
Plus Therapeutics, Inc. PSTV ██% $52M -0.3x 10.2x
Polypid Ltd. PYPD ██% $77M x 7.1x
Avita Medical, Inc. RCEL ██% $143M -5.0x 31.8x
Vivos Inc RDGL ██% $39M x 17.6x
Resmed Inc RMD ██% $34.19B 23.0x 5.4x
Resmed Inc RSMDF ██% $3.82B 2.7x 0.6x
Retinalgenix Technologies Inc. RTGN ██% $60M x x
Retractable Technologies Inc RVP ██% $20M -0.9x 0.3x
Sight Sciences, Inc. SGHT ██% $202M -3.7x 3.2x
Si-Bone, Inc. SIBN ██% $599M -14.3x 3.4x
Sigyn Therapeutics, Inc. SIGY ██% $80K x 0.2x
Sintx Technologies, Inc. SINT ██% $10M x 2.5x
Beauty Health Co SKIN ██% $139M -1.8x 2.1x
Sonoma Pharmaceuticals, Inc. SNOA ██% $4M -5.6x 1.2x
Sanuwave Health, Inc. SNWV ██% $190M x 181.4x
Solventum Corp SOLV ██% $11.55B 7.4x 2.3x
Sensus Healthcare, Inc. SRTS ██% $65M 31.6x 1.4x
Ss Innovations International, Inc. SSII ██% $956M x 25.0x
Strata Skin Sciences, Inc. SSKN ██% $2M -8.0x 1.2x
Neuronetics, Inc. STIM ██% $86M -1.0x 3.1x
Stimcell Energetics Inc. STME ██% $6M x 1031.9x
Sharps Technology Inc. STSS ██% $52M -2.5x 0.1x
Stevanato Group S.P.A. STVN ██% $4.07B x x
Stryker Corp SYK ██% $129.87B 40.0x 11.1x
Tactile Systems Technology Inc TCMD ██% $622M 32.6x 2.8x
Tela Bio, Inc. TELA ██% $33M -1.8x 21.0x
Teleflex Inc TFX ██% $4.95B 31.0x 1.6x
Trisalus Life Sciences, Inc. TLSI ██% $245M -3.6x 28.8x
Trisalus Life Sciences, Inc. TLSIW ██% $62M x -1.9x
Treace Medical Concepts, Inc. TMCI ██% $87M -7.5x 1.0x
Tandem Diabetes Care Inc TNDM ██% $1.45B -17.1x 9.4x
Tenon Medical, Inc. TNON ██% $9M -0.3x 1.9x
T2 Biosystems, Inc. TTOO ██% $210K 0.0x -0.3x
Ufp Technologies Inc UFPT ██% $1.61B 23.6x 3.8x
Qhslab, Inc. USAQ ██% $10M x 133.8x
Utah Medical Products Inc UTMD ██% $205M 17.6x 1.7x
Venus Concept Inc. VERO ██% $560K 0.0x 0.2x
Catheter Precision, Inc. VTAK ██% $2M x 0.4x
Vivos Therapeutics, Inc. VVOS ██% $15M x 6.0x
Vycor Medical Inc VYCO ██% $3M x 36.1x
West Pharmaceutical Services Inc WST ██% $17.15B 34.8x 5.4x
Beyond Air, Inc. XAIR ██% $9M -0.3x 1.1x
Xtant Medical Holdings, Inc. XTNT ██% $88M 50.1x 1.7x
Reveal all forecasts See exact % predictions for all competitors
Sign up free

Frequently Asked Questions - Glaukos Corp Stock Forecast

How accurate are Glaukos Corp stock predictions?

Our AI model shows a -6% Spearman correlation coefficient for GKOS predictions, based on advanced machine learning algorithms trained on over 10 years of market data. This measures the strength of the monotonic relationship between predicted and actual price movements.

What factors influence Glaukos Corp stock price forecasts?

Our analysis considers Glaukos Corp's financial metrics, Industrial Applications and Services sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Glaukos Corp a good investment in 2025?

Based on our AI analysis, Glaukos Corp shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Glaukos Corp forecasts updated?

Glaukos Corp stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

My Portfolio

Investment Dashboard

Loading your portfolio...